Jeffrey D Browning
Overview
Explore the profile of Jeffrey D Browning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
5603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deja S, Fletcher J, Kim C, Kucejova B, Fu X, Mizerska M, et al.
Cell Metab
. 2024 Mar;
36(5):1088-1104.e12.
PMID: 38447582
Acetyl-CoA carboxylase (ACC) promotes prandial liver metabolism by producing malonyl-CoA, a substrate for de novo lipogenesis and an inhibitor of CPT-1-mediated fat oxidation. We report that inhibition of ACC also...
2.
Saha S, Keshvani N, Segar M, Patel K, Fudim M, Rohatgi A, et al.
JACC Heart Fail
. 2024 Jan;
12(5):958-960.
PMID: 38206228
No abstract available.
3.
Fu X, Fletcher J, Deja S, Inigo-Vollmer M, Burgess S, Browning J
J Clin Invest
. 2023 Mar;
133(9).
PMID: 36928190
BACKGROUNDHepatic de novo lipogenesis (DNL) and β-oxidation are tightly coordinated, and their dysregulation is thought to contribute to the pathogenesis of nonalcoholic fatty liver (NAFL). Fasting normally relaxes DNL-mediated inhibition...
4.
Le M, Wu Y, Berry J, Browning J, de Lemos J, Neeland I, et al.
Diabetes Obes Metab
. 2022 Nov;
25(2):586-595.
PMID: 36317522
Aims: To evaluate the associations between liver fat content and cardiometabolic parameters to explore potential threshold values that define metabolically healthy liver fat content, and to examine the association of...
5.
Fu X, Deja S, Fletcher J, Anderson N, Mizerska M, Vale G, et al.
Nat Commun
. 2021 Jun;
12(1):3756.
PMID: 34145255
De novo lipogenesis (DNL) is disrupted in a wide range of human disease. Thus, quantification of DNL may provide insight into mechanisms and guide interventions if it can be performed...
6.
Deja S, Kucejova B, Fu X, Browning J, Young J, Burgess S
Metabolites
. 2021 Apr;
11(5).
PMID: 33924948
Ketogenesis occurs in liver mitochondria where acetyl-CoA molecules, derived from lipid oxidation, are condensed into acetoacetate (AcAc) and reduced to β-hydroxybutyrate (BHB). During carbohydrate scarcity, these two ketones are released...
7.
McHenry S, Park Y, Browning J, Sayuk G, Davidson N
Clin Gastroenterol Hepatol
. 2020 Jan;
18(9):2073-2080.e7.
PMID: 31982611
Background & Aims: Tools have been developed to determine risk for nonalcoholic fatty liver disease (NAFLD) based on imaging, which does not always detect early-grade hepatic steatosis. We aimed to...
8.
Deja S, Fu X, Fletcher J, Kucejova B, Browning J, Young J, et al.
Metab Eng
. 2020 Jan;
59:1-14.
PMID: 31891762
Computational models based on the metabolism of stable isotope tracers can yield valuable insight into the metabolic basis of disease. The complexity of these models is limited by the number...
9.
Fletcher J, Deja S, Satapati S, Fu X, Burgess S, Browning J
JCI Insight
. 2019 Apr;
5.
PMID: 31012869
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, and potentially morbid, disease that affects one-third of the U.S. population. Normal liver safely accommodates lipid excess during fasting or carbohydrate...
10.
Cappel D, Deja S, Duarte J, Kucejova B, Inigo M, Fletcher J, et al.
Cell Metab
. 2019 Apr;
29(6):1291-1305.e8.
PMID: 31006591
The hepatic TCA cycle supports oxidative and biosynthetic metabolism. This dual responsibility requires anaplerotic pathways, such as pyruvate carboxylase (PC), to generate TCA cycle intermediates necessary for biosynthesis without disrupting...